Novo Nordisk A/S $NVO Shares Sold by Verity Asset Management Inc.

Verity Asset Management Inc. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 70.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,076 shares of the company’s stock after selling 28,420 shares during the quarter. Verity Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $614,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Franklin Resources Inc. increased its stake in shares of Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors increased its stake in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $310,199,000. SG Americas Securities LLC increased its stake in shares of Novo Nordisk A/S by 2,101.5% during the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after acquiring an additional 2,274,925 shares during the period. Finally, Clear Street Group Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $56,378,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Erste Group slightly raised FY2026 and FY2027 EPS estimates for NVO, a modest analyst bullish signal that supports near?term earnings expectations and may undercut selling pressure. Erste Group raises estimates
• Positive Sentiment: Novo is presenting new Wegovy data (higher dose and oral semaglutide) and next?generation pipeline updates at the European Congress on Obesity — clinical/label advances and an oral Ozempic rollout are potential growth levers investors can rally around. Wegovy data & pipeline presentation
• Neutral Sentiment: Coverage noting Novo’s strategy (oral Ozempic, pediatric label expansions) highlights management responses to competition; these are strategic positives but their timing and impact remain uncertain. Oral Ozempic & label expansion analysis
• Neutral Sentiment: Broader market and sector moves (e.g., macro/earnings in big tech) are being cited as potential cross?currents for healthcare stocks; these are context factors rather than Novo?specific drivers. Macro/sector context
• Negative Sentiment: Multiple reports flag intensifying pricing pressure in the GLP?1/weight?loss market and falling margins (gross margin down from ~84% to ~80%; net margin from ~36% to ~33%), with direct?to?consumer programs eroding self?pay profitability — a structural margin risk for NVO. Pricing pressure & margin compression preview
• Negative Sentiment: Health Canada approved Dr. Reddy’s generic version of Ozempic — the first G7 generic approval — increasing near?term pricing and market?share risk for Novo’s diabetes/weight?loss franchise. Canada approves generic Ozempic
• Negative Sentiment: Competitor clinical advances are accelerating competitive risk: Eli Lilly’s retatrutide produced surgery?level weight loss in trials and other entrants (e.g., Boehringer’s survodutide) show Wegovy?like results — this intensifies the product race and could pressure prices/volume. Retatrutide milestone & competitive race
• Negative Sentiment: Negative market commentary and pundit views (e.g., Jim Cramer suggesting Novo may lose share to Lilly’s pill) add to bearish investor sentiment and can amplify near?term volatility. Jim Cramer commentary

Novo Nordisk A/S Price Performance

NYSE:NVO traded up $2.07 during trading hours on Thursday, reaching $42.36. 5,947,181 shares of the company’s stock were exchanged, compared to its average volume of 21,999,371. The company has a market capitalization of $189.12 billion, a P/E ratio of 12.25, a price-to-earnings-growth ratio of 9.80 and a beta of 0.73. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The business’s 50-day simple moving average is $38.62 and its two-hundred day simple moving average is $47.36.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were paid a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.14%.

Wall Street Analyst Weigh In

A number of research firms recently commented on NVO. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Finally, Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.